Back to top

Analyst Blog

The Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) recently provided a positive opinion on the approval of Bayer’s (BAYRY - Analyst Report) riociguat in two forms of pulmonary hypertension.

The Committee’s vote was unanimously in favour (11 vs. 0) of the candidate’s approval for the treatment of pulmonary arterial hypertension (PAH) as well as for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH). We note that Bayer had submitted a New Drug Application (NDA) for riociguat in both these indications in Feb 2013.

The regulatory submission of riociguat was based on the basis of positive results from the placebo-controlled pivotal, global phase III CHEST-1 and PATENT-1 studies.

Results from the CHEST-1 study revealed that after 16 weeks, riociguat showed a statistically significant improvement from baseline in the six-minute walk test compared to placebo. Riociguat was also well tolerated during the study.

Bayer enrolled patients suffering from naïve symptomatic PAH as well as those pre-treated with endothelin receptor antagonists (ERAs) or non-intravenous prostanoid monotherapy, for the PATENT-1 study. The study showed a statistically significant improvement in the six-minute walk test from base line after 12 weeks compared to placebo. Bayer published results from both the studies in the New England Journal of Medicine (NEJM) in Jul 2013.

The FDA is currently reviewing the NDA on a priority basis. Though the FDA is not bound to follow the advisory body’s recommendation, it generally does so. Bayer has also submitted a regulatory application for the CTEPH indication of riociguat, in Japan.

Riociguat is expected to face stiff competition in the PAH market on approval. The market already has companies like United Therapeutics Corporation (UTHR - Analyst Report) and Actelion Ltd. (ALIOF).

Bayer, a large cap pharma stock, presently carries a Zacks Rank #3 (Hold). However, another large cap pharma stock, Johnson & Johnson (JNJ - Analyst Report), currently looks better positioned with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%